710328-36-2

Basic information

• Product Name: 4-{4-methyl-6-[3-(4-trifluoromethoxy-phenyl)-acryloylamino]-quinolin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-{4-methyl-6-[3-(4-trifluoromethoxy-phenyl)-acryloylamino]-quinolin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 710328-36-2
• Molecular Weight: 556.585
• Mol File: 710328-36-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-{4-methyl-6-[3-(4-trifluoromethoxy-phenyl)-acryloylamino]-quinolin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{4-methyl-6-[3-(4-trifluoromethoxy-phenyl)-acryloylamino]-quinolin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester(710328-36-2)
• EPA Substance Registry System: 4-{4-methyl-6-[3-(4-trifluoromethoxy-phenyl)-acryloylamino]-quinolin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester(710328-36-2)

Safety Data

• Hazardous Substances Data: 710328-36-2(Hazardous Substances Data)

Upstream product

• 698392-05-1 4-methyl-6-nitro-2-piperazino-quinoline 
• 50693-78-2 4-methyl-2-(piperazin-1-yl)quinoline 
• 634-47-9 2-chloro-4-methylquinoline 
• 865536-44-3 tert-butyl 4-(6-amino-4-methylquinolin-2-yl)piperazine-1-carboxylate 
• 183801-30-1 3-(4-trifluoromethoxyphenyl)acryloyl chloride 

Relevant articles and documents

6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode

Novel 6-acylamino-2-aminoquinoline melanin-concentrating hormone 1 receptor (MCH1R) antagonists were identified by sequential in silico screening with 3D pharmacophore models derived from a series of benzamide antagonists. The structure-activity relationship exploration by synthesis of analogues found structural demands around the western part of the compounds to be quite specific, whereas much structural freedom was found in the eastern part. While these compounds in general suffered from poor solubility properties, the 4-trifluoromethoxy-phenoxyacetamide western appendage provided a favorable combination of activity and solubility properties. The amine in the eastern appendage, originally required by the pharmacophore model and believed to interact with Asp123 in transmembrane 3 of MCH1R, could be removed without diminishing affinity or functional activity of the compounds. Docking studies suggested that the Asp123 interacts preferentially with the nitrogen of the central quinoline. Synthesis and testing of specific analogues supported our revised binding mode hypothesis.